Unacylated ghrelin as therapeutic agent in the treatment of metabolic disorders
AssigneeAlize Pharma SAS
InventorsEzio Ghigo, Aart Jan Van Der Lely, Riccarda Granata
Life of this patent
Estimating the term…
Abstract
An isolated polypeptide comprising any amino acid fragment of unacylated ghrelin or any analog thereof, wherein the polypeptide has an activity selected from the group consisting of a) decreasing blood glucose levels; b) increasing insulin secretion an/or sensitivity; c) binding to insulin-secreting cells; and d) promoting survival of insulin-secreting cells. As well as the use of the polypeptide in the treatment of a disorder associated with impaired glucose metabolism.
Claims28
An isolated polypeptide comprising any amino acid fragment of the amino acid sequence shown in SEQ ID NO:
- 9 or an analog thereof, wherein said polypeptide has at least one activity selected from the group consisting of a) decreasing blood glucose levels;
- b) increasing insulin secretion and/or sensitivity;
- c) binding to insulin-secreting cells;
- and d) promoting survival of insulin-secreting cells.
An isolated polypeptide 5 to 27 amino acid residues in length, said polypeptide comprising the amino acid sequence Glu-His-Gln-Arg-Val.
-40. (canceled)
An isolated polypeptide selected from the group consisting of SEQ ID NO:
- 12, SEQ ID NO:
- 13, SEQ ID NO:
- 14, SEQ ID NO:
- 15, SEQ ID NO:
- 16, SEQ ID NO:
- 17, SEQ ID NO:
- 18, SEQ ID NO:
- 21, SEQ ID NO:
- 22, SEQ ID NO:
- 23, SEQ ID NO:
- 24, SEQ ID NO:
- 25, SEQ ID NO:
- 26, SEQ ID NO:
- 27 and SEQ ID NO:
- 28.
(canceled)
Dependencies are inferred from the claim text.